11/19/2026 | Press release | Distributed by Public on 11/19/2026 05:11
Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion of our financial condition and results of operations for the nine months ended September 30, 2026 and 2025 should be read in conjunction with the unaudited consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under "Cautionary Statements Regarding Forward-Looking Information" appearing earlier in this report, Part I, Item 1A. Risk Factors appearing in our 2025 10-K, and our other filings with the Securities and Exchange Commission. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Such statements are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this report.
Overview
We are a technology company. We design and develop innovative methods to heat plant-based and/or medicant-infused formulations to produce aerosols for the efficient and efficacious inhalation of the plant and medicant constituents contained therein. We have two ways of accomplishing this: 1) at high temperatures via induction without combustion or the constituents of combustion; and 2) at low temperatures, where we heat an inert carrier, producing inhalable, medicant-infused aerosols while maintaining the integrity of the active ingredient(s).
Our high-temperature non-combusting technology is supported by 88 U.S. and international patents and pending patents. Among the applications of our patented and patent-pending technology are those for Heat-not-Burn ("HnB") devices. Independent tests performed by an accredited lab on our system's prototypes supported the benefits of rapid heating, confirmed non-combustion, even at high temperatures, and produced better toxicology results, greater than 99% better, when compared to products requiring combustion. When compared to other non-combusting technologies currently on the market, our results were also superior.
Our low-temperature, aerosolizing technology is supported by 23 U.S. and international patents and pending patents. This portfolio includes intellectual property around device designs and formulations containing a wide variety of herbal and pharmaceutical preparations. The development stage devices feature the ability to verify the user, validate the medicant or pharmaceutical preparation and measure, meter and monitor the proper, prescribed dosage.
Today, we define one of our target markets as the worldwide combustible tobacco market. Grand View Research, a global leader in market reports and industry statistics, estimates that the global tobacco market size was USD 926.0 billion in 2025, and is projected to reach USD 1,144.2 billion in 2033, growing at a CAGR of 2.7% from 2026 to 2033. Our near-term focus is on the heated, non-combusting modified risk tobacco segment, which we believe represents our greatest opportunity for growth and the greatest opportunity to positively impact public health and wellness.
On August 17, 2021, we entered into a Joint Venture Agreement (the "JV Agreement") with Firebird Manufacturing, LLC ("Firebird"), a Barker Group company. Under the terms of the JV Agreement, the parties have agreed to organize, negotiate, and establish a limited liability company joint venture entity (the "Joint Venture Entity") for the purposes of developing, manufacturing, and distributing HnB products in the United States. The Joint Venture Entity will be owned equally by Firebird and the Company. Firebird will be responsible for manufacturing the consumable and distributing both the device and consumables to the retail locations where the product can be lawfully sold in the United States.
Formation of the Joint Venture Entity is subject to formalizing and executing the Joint Venture Operating Agreement and additional agreements, including a license agreement for the use of intellectual property, certain product development agreements, supply agreements and such other agreements as may be necessary to further the purpose of the JV Agreement. The parties anticipate completing the relevant agreements in the first nine months of 2027, although there are no assurances that the parties will complete and formalize these agreements.
On July 13, 2022, the Company entered into a manufacturing contract with Montrade S.p.A. ("Montrade"), an industry-leading designer and manufacturer of machines for a wide range of products, including heated tobacco products (HTP), based in Bologna, Italy, for the manufacture and installation of our proprietary HTP consumables manufacturing equipment. The Company made an initial payment of $589,265. The equipment is completed and is in final assembly testing. On September 30, 2026, the balance owing for construction, installation, travel and training is $291,470.
On June 3, 2025, CQENS entered into an additional agreement with Montrade for the development, manufacture, delivery and installation of a higher volume machine to manufacture consumables for the Company's proprietary, patented and patent-pending HnB system. We made an initial down payment of $1,016,531 on June 4, 2025, and construction commenced. The design phase was completed in November 2025, and we paid the balance for this phase in December 2025, expensing a total of $302,299 for the design phase. On September 30, 2026, the balance remaining under this agreement is $1,839,348.
On December 20, 2023, we entered into a Shareholder Agreement with Asahi to establish CQENS Electronics (Hong Kong) Limited ("CEL"), a Hong Kong company, for design, development and manufacture of our HnB device. CQENS acquired 50% membership of CEL and holds a majority of the board seats, including the chair. Pursuant to the establishment of CEL, CQENS entered into an exclusive, worldwide license agreement with CEL for designing and manufacturing a consumer device consistent with our IP.
In October 2025, we set up a research and development operation in Shenzhen, China to support our US-based research and development efforts and to take our prototype device through the design for manufacturability for mass manufacturing In October 2025, we secured a facility and entered into a two-year lease agreement that commenced in November 2025 with fixed rent for the term of the lease. The monthly rent is approximately $4,878 per month. In January 2026, we formed Shenzhen CQENS, a wholly owned subsidiary and foreign entity in China, for these research and development activities in Shenzhen, China.
As the largest category within the global inhalation market is the combustible tobacco market, comprising over 90% of the total inhalation market, our near-term focus is on this segment, which represents the greatest opportunity for growth and the greatest opportunity to positively impact public health and wellness. To this end, we have added three critical senior executives to our management team with decades of experience in the tobacco and next-generation sectors filling our Chief Operating Officer, Chief Commercial Officer and Chief Technical Officer roles. Their experience is extensive and includes executing global commercial strategy; development and scaling of reduced-risk product portfolios across multiple international markets; and machinery and manufacturing solutions in the tobacco and next-generation product sectors.
Further, we have assembled a team of engineers in Shenzhen, China, to work closely with our US-based research and development engineering team and our Hong Kong-based joint venture entity, CEL, to complete the design for manufacturability of our launch products.
We are also working with our Hong Kong joint venture to secure national and international certification markings.
Our joint venture partner in Hong Kong has sourced and secured suppliers for the device components, completed the tooling and is focused on the production process for mass manufacturing of our devices.
US-based Firebird is in the midst of construction of a new and much larger facility where the consumable manufacturing production line equipment will be installed for the mass production of our consumables.
We have retained the services of a related party, Plexus International, to consult with us in the design and development of our quality management systems within our corporate office and throughout our joint ventures and reaching to our suppliers and will work to ensure the manufacturing facilities are GMP compliant.
We have retained a leading investment banker and capital markets firm, to explore the opportunities to secure a long-term strategic partnership or to secure the capital resources necessary to successfully commercialize our products. We have not identified any opportunities as of the date of this report.
We have retained McKinney Regulatory Science Advisors LLC to consult, conduct trials and testing, and assist us as we navigate through the PMTA process. We anticipate conducting trials and testing in the first quarter of 2027.
Going concern
For the first nine months of 2026, we reported a consolidated net loss of $4,386,320 and net cash used in operations of $3,315,545 compared to a net loss of $5,596,884 and net cash used in operations of $2,833,350 for the first three quarters of 2025. At September 30, 2026, we had cash on hand of $5,606,758 and an accumulated deficit of $52,066,381. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2025, contains an explanatory paragraph regarding our ability to continue as a going concern based upon our recurring losses and no source of revenues which are sufficient to cover our operating costs and loans due on demand. These factors, among others, raise substantial doubt about our ability to continue as a going concern 12-months after the date of these consolidated financial statements are issued.Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Results of operations
We did not generate any revenues from our operations in the first nine months of 2026 or 2025.
Our total operating expenses for the three months ended September 30, 2026 increased 32.0% over those reported for the same period in 2025. This is attributable to an increase of 134.1% in general and administrative expenses, an increase of 51.3% in research and development and a 38.1% decrease in professional fees. General and administrative expenses increased primarily from increases of $315,925 in compensation expense, $15,248 in payroll, taxes and fees, $16,895 in rent, and $12,818 in amortization expenses. Research and development costs increased $211,873 as more was spent on supplies and materials, firmware testing and engineering time in the third quarter of 2026. The $199,824 decrease in professional fees in the third quarter of 2026 versus the same period in 2025 is due to the reduction in options issued for services of $215,235 and an increase of $40,456 in consulting, legal and other professional services utilized during the quarter.
For the first nine months of 2026, total operating expenses decreased 23.3% or $1,356,243 from those reported in the first nine months of 2025. The decrease is principally due to professional fees decreasing 62.8% or $2,313,645 and includes reductions in shares for services of $1,203,380, stock options issued for service $792,041 and $318,224 for consulting, legal and other professional services. General and administrative expenses increased 78.31% or $712,300 in the first three quarters of 2026 compared to the same period in 2025, primarily due to increases in compensation expenses of $523,121, payroll taxes and fees of $32,067, rent of $55,070 amortization expenses of $32,675. Research and development costs in the first nine months of 2026 increased 19.8% or $245,102 over the first nine months of 2025. This increase was due to an increases in engineering salaries of $210,835, parts and supplies of $245,452 with reductions in consulting services of $120,500 and the manufacturing machine design engineering services of $149,049 that was incurred in 2025.
We expect that our operating expenses will increase as we continue to develop and grow our business and we devote additional resources toward our new technologies and business opportunities, promoting that growth, most notably reflected in anticipated increases in general overhead, salaries for personnel and technical resources, as well as increased costs associated with our SEC reporting obligations. However, as set forth elsewhere in this report, our ability to continue to develop our business and achieve our operational goals is dependent upon our ability to raise significant additional working capital. As the availability of this capital is unknown, we are unable to quantify at this time the expected increases in operating expenses in future periods.
Liquidity and capital resources
As of September 30, 2026, we had $5,606,758 in cash and cash equivalents and a working capital surplus of $3,958,999 compared to $8,914,107 in cash and cash equivalents and a working capital surplus of $7,427,664 at December 31, 2025. Our current liabilities increased $190,467 from December 31, 2025, reflecting an increase in our related party loans, loans payable and accounts payable partly offset by decreases in accrued expenses and the current portion of our lease liability.
Of our cash and cash equivalents at September 30, 2026, $4,474,243 was held by CQENS Technologies Inc. in the United States, $1,040,085 was held by CEL in Hong Kong and $92,430 was held by Shenzhen CQENS in the PRC. Cash held in the United States is available to fund our parent company obligations. CEL is a 50%-owned variable interest entity. Its cash can be used only to settle CEL's obligations. Accordingly, we do not consider CEL's cash to be available to fund our other operations. Cash held by Shenzhen CQENS is subject to PRC foreign exchange regulations, which may restrict or delay our ability to transfer it out of the PRC. We currently intend to use the cash held by CEL and Shenzhen CQENS to fund their own operations.
Our source of operating capital in the first nine months of 2026 came from cash on hand at the end of 2025 of $8,914,107, the sale of 17,700 shares of common stock for gross proceeds of $354,000, borrowing from related parties of $140,687, and $89,507 from an un-related lender, net of loan repayments of $51,492, and earned interest of $125,033 which was partially offset by other taxes and surcharges of $36,591. Our source of operating capital in the first nine months of 2025 came from cash on hand at the end of 2024 of $4,596,556; the sale of 519,500 shares of common stock for gross proceeds of $10,390,000 of which $9,540,000 was received in the first nine months of 2025 and $850,000 that was received as an investor deposit and included in cash on hand at the end of 2024, borrowing from a related party of $61,943, and earned interest of $259,044 which was partially offset by other taxes and surcharges of $24,923.
Our working capital includes $1,126,201 of related party loans and $317,366 of loans payable, all of which are due on demand. In the first nine months of 2026, we repaid $50,000 of our loan from Xten Capital Group, a related party, leaving a balance of $850,000. CEL borrowed $503 from Ann Liu, its managing director, and $140,184 from Asahi, and owed them $79,179 and $197,022, respectively, at September 30, 2026. Shenzhen CQENS borrowed $89,507 from, and repaid $1,492 to, unrelated lenders, and owed them $317,366 at September 30, 2026. The loans are unsecured and non-interest bearing, and we are using the funds for working capital. If our lenders were to demand repayment, we would be required to fund repayment from our available cash.
Our known cash requirements over the next twelve months include $2,130,818 of remaining payments under our agreements with Montrade for consumables manufacturing equipment and rent under our Zhuhai leases of approximately $134,000 per year once the rent-free periods end in April 2027 and October 2027. They also include the continued costs of our PMTA process, research and development and general operations; we used $3,315,545 of cash in operating activities in the first nine months of 2026, or approximately $368,000 per month.
Our existing cash is not expected to be sufficient to fund our planned operations and obligations for at least one year after the date of this report, we will need to raise $10,000,000 to $15,000,000 in additional capital to fund operations within the next year, including for the commercialization of our products. There can be no assurance that we will be able to obtain such capital on reasonable terms, or at all. Circumstances beyond our control, such as regulatory changes, delays or additional regulatory requirements, could also increase our capital needs. Without sufficient capital, we may be unable to fund our operating expenses and continued development of our products or to satisfy our obligations as they become due within the next year. If we are unable to obtain sufficient capital, our ability to continue as a going concern will be in jeopardy.
The ability of the Company to continue as a going concern is dependent upon the Company obtaining adequate capital to fund operating losses until it becomes profitable. As the Company is not generating revenues, continued activities and expenditures to bring product(s) to market as soon as we are able is important.
Summary of cash flows
| September 30, 2026 | September 30, 2025 | |||||||
| Net cash (used) in operating activities | $ | (3,315,545 | ) | $ | (2,833,350 | ) | ||
| Net cash (used) in investing activities | $ | (534,093 | ) | $ | (2,081,602 | ) | ||
| Net cash provided by financing activities | $ | 532,702 | $ | 9,561,943 | ||||
Our cash used in operating activities increased 17.0% in the first nine months of 2026 compared to the first nine months of 2025. During these time periods, we primarily used the cash to fund our net losses.
In the first three quarters of 2026, there was $534,093 net cash used in investing activities from the capitalization of our intellectual property, along with additions to other intangible assets, construction-in-progress asset and property, plant, and equipment compared to net cash used in investing activities of $2,081,602 in the same period in 2025 for capitalization of our intellectual property and increases to equipment under construction.
In the first nine months of 2026, we had net cash provided by financing activities of $532,703 from the sale of our common stock and net borrowing from related and non-related parties. We had net cash provided by financing activities in the first nine months of 2025 of $9,561,943 from the sale of our common stock and net borrowing from related parties.
Critical accounting estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, as well as related disclosures. Key estimates and judgments reflected in our financial statements include impairment of long-lived assets, the $20.00 per share common stock fair value used for option and warrant valuations, the VIE consolidation assessment of CEL, the capitalization of intellectual property and construction in progress, and our going concern evaluation. Because these determinations are grounded in observable inputs and objective U.S. GAAP criteria without significant estimation uncertainty, and we also have other key accounting policies, none of these policies are deemed to be critical accounting policies or critical estimates.
Off balance sheet arrangements
As of the date of this report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.